secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2026-06-10T20:15:25+00:00
Accession:  0001683168-26-004707
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports FY2026 net loss $7.2M, cash $5.0M; oncology study enters final cohort
--------------------------------------------------------------------------------

- Net loss $7.2M vs $13.4M prior year; operating expenses down 21.9% to $7.3M.
- Cash $5.0M at March 31; subsequent $1.85M raised via ATM program.
- Australian oncology study advanced to Cohort 3; first patient treated in final dosing cohort.
- Patents issued in US and Europe for Hemopurifier in long COVID/coronavirus, extending protection to 2040s.
- Preclinical studies for rheumatoid arthritis and chronic kidney disease underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/0001683168-26-004707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316826004707/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-004707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer